The Medical Letter on Drugs and Therapeutics
Nutritional Support for Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

An advertisement in a recent issue of Ophthalmology introduces PreserVision Eye Vitamin AREDS 2 Formula from Bausch & Lomb. No specific indication is mentioned, but the ad states that “…[the new product] builds on the original PreserVision Eye Vitamin AREDS Formula, the only formula proven to slow the progression of moderate-to-advanced AMD.”

BACKGROUND — The first AREDS trial, supported by the National Eye Institute and Bausch & Lomb, recruited 3640 patients 55-80 years old who had age-related macular degeneration (AMD) at various stages. Patients were randomized (double masked) to: (1) antioxidants at doses 5 to 15 times higher than the RDA (vitamin C 500 mg, vitamin E 400 IU and beta carotene 15 mg), (2) zinc oxide 80 mg plus cupric oxide 2 mg, (3) antioxidants plus zinc and copper or (4) placebo. The primary endpoints were progression to advanced AMD and moderate loss of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nutritional Support for Macular Degeneration
Article code: 1344b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian